by Raynovich Rod | Feb 2, 2012 | BIOgraph, Clinical Diagnostics and Tools
Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX) announced today that it has entered purchase agreements with private investors including current holders to raise...
by Raynovich Rod | Jan 25, 2012 | 2024-25 Life Science Portfolios, BIOgraph, Clinical Diagnostics and Tools
M&A Theme Provides Underlying Bid to Market Roche Holding, the most diversified diagnostics and pharmaceutical Company with an aggressive leveraged strategy for the molecular basis of disease and personalized medicine has offered $5.7B for the leading Company in...
by Raynovich Rod | Jan 12, 2012 | BIOgraph, Clinical Diagnostics and Tools
You read about it every year, and always there are skeptics, but in Q4 2011 to Q 2012 the “January effect ” rally for small cap and life science stocks were big winners. Why does this happen? Not so important just that it does happen. Here are our December...
by Raynovich Rod | Jan 11, 2012 | BIOgraph, Clinical Diagnostics and Tools
Life Science stocks got a boost from news and presentations at the J.P.Morgan Healthcare Conference and most stocks from the Rayno Life Science Portfolio were up.(see our “January Effect” trades mentioned in December). Leading life science tools companies...
by Raynovich Rod | Dec 28, 2011 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Here are some key points from our 2011 Biotech Stock Review posted in Investor Uprising: Winners from the 2011 Rayno Life Science Portfolio: Abaxis (ABAX), Alexion(ALXN), Amgen (AMGN), Biogen(BIIB), Bristol-Myers (BMY),Celera(acquired),Cephalon (acquired) Cubist...
by Raynovich Rod | Dec 22, 2011 | BIOgraph, Clinical Diagnostics and Tools
Life Sciences: Biopharmaceutical Stocks are Hot, Tools and DX are Not We recommended avoiding the Tools/Dx sector several weeks ago as they were lagging biopharmaceutical stocks due to earnings misses, concerns about NIH finding for R&D, and lack of exciting new...
by Raynovich Rod | Dec 5, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Illumina (ILMN $30.23) shares spiked today on takeover speculation. The shares were whacked in July and the stock is down 52% YTD on an earnings miss with no guidance. Revenue estimates from analysts are in the $1B range for 2011 so with the current Market Cap of...
by Raynovich Rod | Dec 2, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
No new buys, currently on HOLD list: ABAX, EXAS, NEOG, QDEL, SRLS. Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update | Raygent.com Outperformers YTD: ABAX up 2.9%,CPHD up 51%, EXAS up 42%, GHDX up 31%, GPRO up 9%, LMNX up 13%, QDEL up 25%,...
by Rod Raynovich | Oct 11, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
11/21/11 The diagnostics and tools sector remain weak trading down about 1.9% slightly better than NASDAQ down 2.5%. Within the life sciences we prefer biopharmaceutical stocks because of M&A potential and less sensitivity to earnings. From October 11,2011...
by Rod Raynovich | Oct 10, 2011 | Clinical Diagnostics and Tools
There is an excellent Guide to Biotech Investing on the Investor Uprising blog. You will need a IU account to view the document http://www.investoruprising.com/document.asp?doc_id=206689
